OCT 28, 2015 11:00 AM PDT

The Hidden Effects of Epigenetic Discoveries

SPONSORED BY: Rockland antibodies and assays, Rockland antibodies and assays
22 52 9027

  • Assistant Professor, Emory University
      Christopher Scharer received his B.Sc (2004) and Ph.D (2009) from Emory University in Atlanta, Georgia. During his graduate work he studied the role of oncogenic transcription factors under the mentorship of Dr. Carlos Moreno. In 2009, he joined Dr. Jeremy Boss' laboratory as a Postdoctoral fellow, later progressing to Instructor (2014), and more recently Assistant Professor (2015). In Dr. Boss' lab his research focused on identifying epigenetic mechanisms of T and B cell differentiation. Currently, Dr. Scharer's research focuses on improving and adapting sequencing applications for low cell input numbers, including ATAC-seq, ChIP-seq, Methyl-seq and RNA-seq. He currently leads an effort to integrate these epigenome-mapping technologies to understand normal immune function and autoimmune diseases. Through identifying pathogenic epigenetic signatures using a system's biology approach, he aims to reverse engineer the environmental stimuli that impact human disease and discover novel biomarkers and therapeutic targets.
    • Research Assistant Professor, School of Pharmacy at Temple University
        Dr. Carlos A. Barrero is a Research Assistant Professor at the School of Pharmacy at Temple University. His research interests focus on applying proteomics, metabolomics and bioinformatics technologies for the study of pathological mechanisms of different diseases. He received his M.D. from Caldas University in Colombia in 2001. Prior to joined Temple University in 2006, Dr. Barrero was a research Fellow at the Fundacion Instituto de Inmmunologia de Colombia, were he applied proteomics for the development of novel malaria and tuberculosis vaccines. Dr. Barrero complete his Post-Doctoral training in Dr. Salim Merali laboratory in the department of Biochemistry at Temple University, were he acquired state-of-the-art knowledge in proteomics and metabolomics by using mass spectrometry. Later in 2009 he become an Associate Scientist and recently was appointed as a Research Assistant Professor at the Temple University School of Pharmacy in June 2014.
        Dr. Barrero has been fully supported by grant funding to date at Temple and has contributed to a number of important developments of basic and translational science. Dr. Barrero has been a co-author on 31 publications in high impact journals and has been a major contributor to 4 patent applications submitted by Temple University. Dr. Barrero has made substantial impact to the knowledge of pathological mechanisms underlying chronic obstructive pulmonary disease (COPD). Specifically, his proteomics results identified new possible plasma biomarkers for COPD and elucidated that histone H3.3 protein is increased in COPD and plays a critical role in the progression of the disease. His current interest is to explore the ability of H3.3 to be used as an early marker and as a therapeutic target for COPD progression, which will have a direct translational application and will assist greatly in the identification and treatment of patients with this disease. Dr. Barrero has made similar contributions in the areas of obesity and in HIV-AIDS.
      • Research Scientist, R&D, Advanced Cell Diagnostics (ACD)
          Dr. Jeffrey Kim is an research scientist at Advanced Cell Diagnostics (ACD) in Newark, California. Dr. Kim obtained his Ph.D. in molecular biology investigating how nutrient metabolism impacts gene expression to alter chronic disease states at the University of Connecticut. Afterwards, he completed a postdoctoral fellowship at the University of California-Davis looking at oncometabolite metabolism in renal cell carcinoma as well as the role of docosahexaenoic acid-derived metabolites on tumor angiogenesis. In addition, he previously completed a fellowship at the National Institutes of Health examining the influence of various fatty acids on brain development by combining the powerful tools of mass spectrometry and imaging.

        DATE: October 28th, 2015
        TIME: 11am Pacific time, 2pm Eastern time

        New discoveries uncover that exposure to current environmental, dietary, behavioral, and medical conditions can significantly affect the future development and health of an individual and their offspring. Which correspondingly means, that the development and health of an individual is influenced by past experiences of that individual's parents.
        Research shows, that enriching environments offer opportunities for improved sensory, motor, cognitive, and social stimulation. This improved stimulation has a multitude of positive effects, from increasing learning and memory, to reducing the possibility of acquiring depression or many brain disorders including Huntington's diseases, Alzheimer's and stroke. In this webinar we will talk about how current investigation in Epigenetics can affect patient treatment and impacts research in general.

        Show Resources
        Loading Comments...